| __timestamp | Telix Pharmaceuticals Limited | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 22622695 | 125883000 |
| Thursday, January 1, 2015 | 24863028 | 69036000 |
| Friday, January 1, 2016 | 21351001 | 72700000 |
| Sunday, January 1, 2017 | 53837297 | 105700000 |
| Monday, January 1, 2018 | 16080096 | 198700000 |
| Tuesday, January 1, 2019 | 18525736 | 117600000 |
| Wednesday, January 1, 2020 | 2024000 | 108100000 |
| Friday, January 1, 2021 | 2548000 | 122500000 |
| Saturday, January 1, 2022 | 61556000 | 146700000 |
| Sunday, January 1, 2023 | 188157000 | 257500000 |
Unleashing the power of data
In the ever-evolving landscape of biopharmaceuticals, understanding cost dynamics is crucial. United Therapeutics Corporation and Telix Pharmaceuticals Limited, two industry stalwarts, have shown intriguing trends in their cost of revenue over the past decade. From 2014 to 2023, United Therapeutics consistently maintained higher costs, peaking in 2023 with a 104% increase from 2015. Meanwhile, Telix Pharmaceuticals exhibited a dramatic surge, with costs skyrocketing by over 700% from 2014 to 2023. This stark contrast highlights differing strategic approaches: United Therapeutics' steady growth versus Telix's aggressive expansion. Such insights are invaluable for investors and industry analysts alike, offering a window into the operational strategies of these companies. As the biopharmaceutical sector continues to innovate, keeping an eye on cost trends will be essential for predicting future market movements.
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and United Therapeutics Corporation
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and United Therapeutics Corporation's Expenses
Cost of Revenue: Key Insights for United Therapeutics Corporation and Walgreens Boots Alliance, Inc.
United Therapeutics Corporation vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: United Therapeutics Corporation vs CRISPR Therapeutics AG
Analyzing Cost of Revenue: United Therapeutics Corporation and MorphoSys AG
Cost of Revenue Comparison: United Therapeutics Corporation vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: United Therapeutics Corporation and Wave Life Sciences Ltd.
Cost Insights: Breaking Down Incyte Corporation and Telix Pharmaceuticals Limited's Expenses
Analyzing Cost of Revenue: Pharming Group N.V. and Telix Pharmaceuticals Limited
Cost of Revenue: Key Insights for Telix Pharmaceuticals Limited and Alkermes plc
Cost Insights: Breaking Down Telix Pharmaceuticals Limited and Perrigo Company plc's Expenses